Citius Pharmaceuticals Files 8-K with Exhibits
Ticker: CTXR · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1506251
Sentiment: neutral
Topics: reporting, financials, exhibits
TL;DR
Citius Pharma filed an 8-K, mostly just exhibits and financials. No big news.
AI Summary
On January 7, 2025, Citius Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in Nevada and its principal executive offices are located in Cranford, New Jersey.
Why It Matters
This filing indicates routine corporate reporting, primarily including financial statements and exhibits, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission for financial statements and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Address of principal executive offices
- January 7, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 7, 2025.
In which state is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the address of Citius Pharmaceuticals, Inc.'s principal executive offices?
The address of Citius Pharmaceuticals, Inc.'s principal executive offices is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Does this filing report any specific material events or other significant business updates?
Based on the provided text, this filing primarily concerns the submission of financial statements and exhibits, and does not detail specific material events or other significant business updates.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-01-07 09:11:17
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0226990-8k_citius.htm (8-K) — 34KB
- ea022699001ex99-1_citius.htm (EX-99.1) — 51KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-25-001408.txt ( ) — 285KB
- ctxr-20250107.xsd (EX-101.SCH) — 3KB
- ctxr-20250107_lab.xml (EX-101.LAB) — 33KB
- ctxr-20250107_pre.xml (EX-101.PRE) — 22KB
- ea0226990-8k_citius_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2025 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38174 27-3425913 (Commission File Number) (IRS Employer Identification No.) 11 Commerce Drive , 1st Floor , Cranford , NJ 07016 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code ( 908 ) 967-6677 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On January 7, 2025, Citius Pharmaceuticals, Inc. issued a press release announcing significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated January 7, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: January 7, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2